In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of 55 patients were treated and the combination therapy showed complete molecular response. These data could present a potential paradigm shift in treatment options for Philadelphia chromosome-positive ALL.
Abstract: S114: ‘PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY’ was presented at the EHA annual meeting 2022.
Questions
- What were the aims, design and eligibility criteria of the Phase II study? (00:16-02:11)
- What have we learned from the latest efficacy and safety findings of the study? (02:11-04:12)
Disclosures: Nicholas Short is consultant for Pfizer Inc., Jazz Pharmaceuticals and Sanofi. He has received grant/research support from Takeda Oncology, Astellas Pharma Inc., Xencor and Stemline Therapeutics, and honoraria/honorarium from Novartis, Amgen and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).
